Condensed Consolidated Statement of Operations and Comprehensive loss for the period from July 22, 2023 to September 30, 2023 (Successor) (Unaudited)

As Reported

Adjustment

As Restated

Acquired in-process research and development

$

—

$

348,000

$

348,000

Total operating costs and expenses

(64,286)

348,000

283,714

Income (loss) from operations

64,286

(348,000)

(283,714)

Income (loss) before taxes

50,289

(348,000)

(297,711)

Net income (loss) and comprehensive income (loss)

50,289

(348,000)

(297,711)

Basic and diluted net income (loss) per share

$

1.35

$

(9.36)

$

(8.01)

Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Deficit for the period from July 22, 2023 to September 30, 2023 (Successor) (Unaudited)

As Reported

Adjustment

As Restated

Accumulated deficit, balance as of July 22, 2023 (Successor)

$

(180,856)

$

348,000

$

167,144

Net income (loss)

$

50,289

$

(348,000)

$

(297,711)